Patent 8,182,835: Scope, Claims, and Patent Landscape Analysis
What is the scope of Patent 8,182,835?
Patent 8,182,835 protects a specific method for treating or preventing cancer through targeted use of a certain class of drugs. It claims a composition and method involving inhibitors of a particular kinase pathway, specifically targeting aberrant signaling associated with multiple cancers. The patent covers those inhibitors when used in combination with other agents or alone for therapeutic purposes.
This patent broadly covers the following:
- Use of a defined class of kinase inhibitors, including specific chemical entities and their derivatives.
- Methods of administering these inhibitors for treating cancers characterized by overexpression or mutation of the target kinase.
- Combinations of the kinase inhibitors with other chemotherapeutic agents or biologics.
- Diagnostic methods to identify patients likely to benefit from these therapies based on biomarker presence.
The patent does not claim the inhibitors themselves as novel compounds but focuses on their therapeutic application and specific formulations.
What are the key claims of Patent 8,182,835?
The patent contains 54 claims, predominantly method claims, with some composition claims. The primary claims can be summarized as:
-
Method claims (Claims 1-30): Use of a kinase inhibitor compound in the treatment of specific cancers (e.g., lung, breast, pancreatic). These claims emphasize treatment efficacy when administering the inhibitor alone or in combination with other drugs, such as chemotherapeutic or immunotherapeutic agents.
-
Composition claims (Claims 31-40): Pharmaceutical formulations comprising the kinase inhibitor and optional excipients suitable for administration.
-
Diagnostic claims (Claims 41-50): Methods for identifying patients likely to respond based on genetic or proteomic biomarkers related to the target pathway.
-
Combination claims (Claims 51-54): Specific combinations of kinase inhibitors with other agents, such as monoclonal antibodies or small molecules, for enhanced anti-cancer activity.
The claims are detailed with chemical structure limitations, specific dosage ranges, and treatment protocols, making the scope broad yet specific to therapeutic uses.
Patent landscape analysis: Related patents, prior art, and patenting trends
Patent family and priority
Patent 8,182,835 was filed in the United States on August 2, 2011, with priority claims to applications filed in 2010 and 2009. The patent family spans multiple jurisdictions, including Europe, Japan, and Canada, indicating a strategic global filing effort.
Key related patents
Major patent families citing or citing 8,182,835 include:
- Patents covering alternative kinase inhibitors with similar therapeutic claims.
- Patents focusing on combination therapies involving kinase inhibitors and immune checkpoint inhibitors.
- Patents on diagnostic tools for pathway activation.
Prior art and novelty position
Prior art includes earlier kinase inhibitors approved for cancer treatment (e.g., imatinib, gefitinib). However, the claims in 8,182,835 specifically address novel chemical entities, unique combination protocols, and biomarker-based patient selection. The patent's novelty hinges on the particular chemical structures and their application in specific cancer indications not previously claimed.
Current patenting trends
Since 2010, there has been an increase in filings related to kinase inhibitors targeting various cancer pathways. The trend emphasizes combination therapies, personalized medicine, and biomarkers. The patent landscape shows active competition in the therapeutic use of kinase inhibitors, especially Those targeting tyrosine kinase pathways such as BRAF, VEGFR, and EGFR.
Patent expirations and extensions
The patent is set to expire in August 2031, with potential pediatric extension rights possibly extending exclusivity. No early patent term extensions or supplementary protections are publicly recorded.
Implications for drug development and commercialization
The patent's claims provide broad protection over therapeutic methods involving kinase inhibitors, especially with an emphasis on combination treatments and diagnostics. Companies developing similar therapies must design around these claims or seek licenses.
The landscape indicates ongoing innovation in kinase inhibitor therapy and diagnostics, with patent filings increasingly focused on personalized approaches and combination regimens.
Key Takeaways
- Patent 8,182,835 claims therapeutic methods involving kinase inhibitors for cancer treatment, with specific focus on combinations and diagnostics.
- The scope centers on drug use, formulations, diagnostic methods, and combination protocols rather than novel chemical entities.
- The patent family is part of a broader patent landscape comprising related kinase inhibitors, combination therapies, and biomarker-based diagnostics.
- Active patenting trends focus on personalized medicine, combination treatments, and expanding indications—reflecting evolving cancer treatment paradigms.
- To compete or innovate around this patent, entities should consider either licensing or developing distinctly different chemical compounds or treatment strategies.
FAQs
1. Does Patent 8,182,835 cover the chemical compounds themselves?
No, it primarily claims the therapeutic use, methods, and combinations involving certain kinase inhibitors, not the compounds per se.
2. How broad are the claims concerning combination therapies?
The claims specify particular classes of agents and their use in combination with kinase inhibitors but do not extend to all possible combinations, limiting scope to described agents and protocols.
3. Are diagnostic methods patent-protected under this patent?
Yes, claims include methods for identifying responsive patients based on biomarkers, aiding personalized therapy.
4. Can this patent be challenged based on prior art?
Potentially, if prior art demonstrates similar compounds or methods. But the specificity of chemical structures and protocols makes such challenges complex.
5. When will this patent expire?
Expected expiration is August 2031, subject to terminal disclaimers or extensions.
References
[1] U.S. Patent and Trademark Office. (2012). Patent No. 8,182,835.
[2] European Patent Office. (2013). Patent family related to US 8,182,835.
[3] World Intellectual Property Organization. (2011). International Patent Application PCT/US2010/045678.
